Vericel Co. (NASDAQ:VCEL) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its stake in Vericel Co. (NASDAQ:VCEL) by 7.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 578,712 shares of the biotechnology company’s stock after selling 44,915 shares during the period. Victory Capital Management Inc. owned 1.17% of Vericel worth $31,777,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of VCEL. Arcadia Investment Management Corp MI acquired a new stake in Vericel in the 4th quarter worth approximately $48,000. Farther Finance Advisors LLC boosted its stake in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after buying an additional 1,058 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Vericel during the 3rd quarter worth approximately $92,000. Finally, Geneos Wealth Management Inc. raised its position in Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company’s stock worth $138,000 after buying an additional 2,240 shares during the last quarter.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the completion of the sale, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. The trade was a 8.59 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares of the company’s stock, valued at approximately $74,759.94. The trade was a 47.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,500 shares of company stock valued at $466,200 in the last three months. 5.20% of the stock is currently owned by corporate insiders.

Vericel Price Performance

NASDAQ:VCEL opened at $49.56 on Monday. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of 826.14 and a beta of 1.78. The company has a 50 day moving average price of $56.48 and a 200-day moving average price of $51.98. Vericel Co. has a 1-year low of $39.12 and a 1-year high of $63.00.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on VCEL. BTIG Research raised their price target on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a research report on Saturday. Stephens reissued an “overweight” rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial reissued a “buy” rating and set a $61.00 price target (down from $67.00) on shares of Vericel in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.29.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.